HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $65 Price Target
Halozyme Therapeutics Analyst Ratings
Halozyme Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $65 Price Target
Wells Fargo Adjusts Price Target on Halozyme Therapeutics to $58 From $48, Maintains Overweight Rating
Halozyme Downgraded at Piper Sandler Despite Guidance Raise
Halozyme Therapeutics Analyst Ratings
Piper Sandler Downgrades Halozyme Therapeutics to Neutral, Raises Price Target to $51
Halozyme Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $50 Price Target
Halozyme Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $50 Price Target
J.P. Morgan Securities: Maintaining the Halozyme Therapeutics (HALO.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $72.00 to $71.00.
Halozyme Therapeutics Analyst Ratings
JMP Securities Maintains Market Outperform on Halozyme Therapeutics, Lowers Price Target to $71
HC Wainwright & Co. : The Halozyme Therapeutics (HALO.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $50.00.
Halozyme Therapeutics Analyst Ratings
Halozyme Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $50 Price Target
Halozyme Therapeutics Analyst Ratings